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Background: Although a psychiatric history might be an independent risk factor for
COVID-19 infection and mortality, no studies have systematically investigated how
different clusters of pre-existing mental disorders may affect COVID-19 clinical outcomes
or showed how the coexistence of mental disorder clusters is related to COVID-19
clinical outcomes.
Methods: Using a retrospective cohort study design, a total of 476,775 adult patients
with lab-confirmed and probable COVID-19 between March 06, 2020 and April 14, 2021
in South Carolina, United States were included in the current study. The electronic health
record data of COVID-19 patients were linked to all payer-based claims data through the
SC Revenue and Fiscal Affairs Office. Pre-existing mental disorder diagnoses from Jan
2, 2019 to Jan 14, 2021 were extracted from the patients’ healthcare utilization data via
ICD-10 codes.
Results: There is an elevated risk of COVID-19-related hospitalization and death among
participants with pre-existing mental disorders adjusting for key socio-demographic and
comorbidity covariates. Co-occurrence of any two clusters was positively associated with
COVID-19-related hospitalization and death. The odds ratio of being hospitalized was
1.26 (95% CI: 1.151, 1.383) for patients with internalizing and externalizing disorders,
1.65 (95% CI: 1.298, 2.092) for internalizing and thought disorders, 1.76 (95% CI: 1.217,
2.542) for externalizing and thought disorders, and 1.64 (95% CI: 1.274, 2.118) for three
clusters of mental disorders.
Conclusions: Pre-existing internalizing disorders and thought disorders are positively
related to COVID-19 hospitalization and death. Co-occurrence of any two clusters of
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mental disorders have elevated risk of COVID-19-related hospitalization and death
compared to those with a single cluster.
Keywords: pre-existing mental disorders, co-occurrence, COVID-19 outcomes, electronic health records (EHRs),
United States

INTRODUCTION

cluster (22). A good understanding of the impact of mental
disorders (and their co-occurrences) on COVID-19 outcomes
will be important to inform effective surveillance, prevention,
and treatment.
Therefore, the current study aims to exam: (1) how each
cluster of pre-existing mental disorders (i.e., internalizing
disorders, externalizing disorders, and thought disorders)
is associated with COVID-19 clinical outcomes; and (2)
how the co-occurrences of different mental disorder clusters
(i.e., internalizing & externalizing, internalizing & thought,
externalizing & thought, internalizing & externalizing &
thought) are associated with COVID-19 clinical outcomes. Using
population-based electronic health records (EHR) data from a
statewide cohort of all confirmed and probable COVID-19 adult
cases in South Carolina (SC), United States from March 6, 2020
to April 14, 2021, our study will provide real-world evidence
to inform the healthcare delivery for people with pre-existing
mental disorders in the context of COVID-19 pandemic and
future public health emergencies.

The coronavirus disease 2019 (COVID-19) caused by the
severe acute respiratory syndrome coronavirus (SARS-CoV-2)
has rapidly become a global public health crisis. Individuals
with existing mental disorders may be particularly vulnerable
to COVID-19 (1–7). A growing body of research focuses
on the impact of pre-existing mental disorders on COVID19 clinical outcomes among this vulnerable population. Preexisting mental disorders were associated with risk of severe
COVID-19 clinical outcomes (hospitalization, intensive care unit
[ICU] admission, invasive ventilation, or death) (8–11). Recent
studies also found a higher mortality rate among COVID19 patients with mental disorders compared to the general
population (12, 13). Likewise, hospitalized COVID-19 patients
with severe psychiatric disorders died at a younger age than those
without a psychiatric disorder after controlling for other clinically
relevant variables.
Although existing literature suggests that a psychiatric
diagnosis might be an independent risk factor for COVID-19
infection and mortality, some knowledge gaps remain. First, no
studies have systematically investigated how different clusters
of pre-existing mental disorders may affect COVID-19 clinical
outcomes (14). Increasing evidence reveals that sets of mental
disorders and symptoms predictably co-occur (15, 16). That is,
some mental disorders are more highly correlated with each
other. Studies about the structure of psychopathology result
in the incorporation of disorder clusters in research and the
growth of transdiagnostic treatment (17, 18). According to an
existing psychopathology structure model (i.e., “three factor
model”), mental disorders can be organized into three broad
clusters (or higher-order factors): internalizing disorders (e.g.,
depression, generalized anxiety disorder, panic disorder, and
post-traumatic stress disorder), externalizing disorders (e.g.,
conduct disorder, alcohol dependence, cannabis dependence,
other drug dependence, and tobacco addiction), and thought
disorders [e.g., obsessive-compulsive disorder (OCD), mania,
and schizophrenia] (19–21). Examining the unique roles of
these mental disorder clusters in affecting COVID-19 clinical
outcomes will advance our understanding of the intersection of
mental disorders and infectious diseases in the context of the
COVID-19 pandemic.
Second, data are limited on how the co-occurrence of
different mental disorder clusters is related to COVID-19 clinical
outcomes. Co-occurrence of different mental disorders is not
infrequent events. Literature suggests that the rates of cooccurrence of two or more clusters of disorders are very high in
psychiatry (e.g., ∼50%). That is, about one half of the patients
who meet the diagnostic criteria for one disorder in a cluster
meet the diagnostic criteria for a second disorder in a different
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METHODS
Data Source
Data for this study were extracted from the SC statewide
Case Report Form (CRF; “Human Infection With 2019 Novel
Coronavirus Case Report Form”) issued by the SC Department of
Health and Environmental Control (SC DHEC) (23). Reporting
of COVID-19 cases to the SC DHEC is mandated by SC Law
and Regulations (24). Specifically, all the key information of
COVID-19 cases was collected through the CRF distributed
within the SC Infectious Disease and Outbreak Network
(SCION), the statewide infectious disease reporting system.
The key information of lab-confirmed and probable COVID19 cases contained in the CRF include the case classification
and identification, case demographics, clinical course, symptoms,
past medical history, and social history. Hospitalization, ICU
and death information were also either provided in the CRF
or collected during case interviews by DHEC staff. The criteria
of case ascertainment follow the standardized surveillance case
definition of COVID-19 (25). The SC Revenue and Fiscal Affairs
(RFA) office is the state agency that receives all the medical claims
data as required by the state law. The SC RFA office linked the
dataset of COVID-19 cases to all medical claim data following our
approved research protocol. All data linkage process complied
with the Health Insurance Portability and Accountability Act
(HIPPA) regulations to protect data privacy and security. After
completing the data linkage, the RFA provided the research
team with the de-identified dataset for data analysis. The study
protocol was approved by the institutional review board at
University of South Carolina and SC RFA and SC DHEC who
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serve as the regulatory bodies of the statewide EHR data. A total
of 476,775 adult patients (≥18 years of age) with lab-confirmed
and probable COVID-19 between March 06, 2020 and April 14,
2021 were included in the current study.

TABLE 1 | Summary of ICD-10 codes used for cluster determination.
Type/cluster
Internalizing disorders

Disease name
Depression

F32, F33

Generalized anxiety disorder

Measures
Pre-existing Mental Disorders
ICD 10th edition (ICD-10) codes of pre-existing mental disorder
diagnoses from January 2, 2019 to January 14, 2021 were
extracted from the patients’ healthcare utilization data (See
Table 1 for ICD-10 codes). A binary variable (yes/no) was created
for each of the existing mental disorder clusters. Patients who
had diagnosis in least one mental disorder before the COVID19 diagnosis were defined as “Yes” for this variable and the rest
were defined as “No.”

Externalizing disorders

ICD-10 code

F41.1

Social phobia

F40.1

Simple phobia

F40.298

Agoraphobia

F40.0

Panic disorder

F41.1

Post-traumatic stress
disorder

F43.1

Eating disorders

F50

Attentiondeficit/hyperactivity
disorder

F90

Conduct disorder

F91

COVID-19 Clinical Outcomes

Alcohol dependence

F10.2

Key COVID-19 clinical outcomes included severity,
hospitalization, and death. COVID-19 severity was categorized
as asymptomatic, mild, and moderate/severe (26). COVID19 patients who showed no symptoms were categorized as
asymptomatic; those who presented any of various mild signs
and symptoms of COVID-19 (e.g., fever, cough, sore throat,
malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss
of taste, and smell) were categorized as mild; and those with
difficulty breathing or developed pneumonia or acute respiratory
distress syndrome (ARDS) were categorized as moderate/severe.
Hospitalization was assessed using the response to the CRF
question “Was the patient hospitalized?” (“yes,” “no,” or
“unknown”). We then dichotomized the hospitalization (1 =
yes, 0 = no or unknown). Death was measured by the response
to question “Did the patient die as a result of this illness?” (“yes,”
“no,” or “unknown”). It was dichotomized in the same way (1 =
death, 0 = alive or unknown).

Cannabis dependence

F12.2

Other drug dependence

F19.2

Tobacco dependence

F17.2

Obsessive-compulsive
disorder

F42

Thought disorders

Mania

F20–29

and frequency counts and percentages for the categorical
variables. Differences in key COVID-19 clinical outcomes (i.e.,
severity, hospitalization, and death) by each mental disorder
cluster and covariates were tested using a t-test or Chi-square
tests as appropriate. A Venn Diagram was created to illustrate
patterns of co-occurrence of different clusters of mental disorders
among the participants. We examined the association between
pre-existing mental disorder cluster and each of the COVID-19
clinical outcomes using logistic regression or multinomial logistic
regressions as appropriate separately. Models were adjusted for
age, gender, race, ethnicity, residence, smoking status, and CCI
score. The models for COVID-19 hospitalization and death
were also adjusted for the COVID-19 severity. Adjusted odds
ratios (aOR) and their 95% confidence intervals (95% CI) are
presented. To investigate the impact of co-occurrence of different
mental disorder clusters, we further examined the three-way
interactions among three clusters of mental disorders in the
final regression models. Forest plots were created based on the
final regression models to visualize the impacts to COVID-19
clinical outcomes by all the factors including pre-existing mental
disorders, co-occurrence of different mental disorder clusters,
and other covariates. It is notable that not all the COVID-19 cases
included in the current study have been linked to the medical
claim data. Only the individuals who had visited healthcare
service system in SC reported health insurance status and had
other pre-exiting medical records. Therefore, we ran additional
subgroup analysis for the individuals with health visits and had
insurance information and compared the results with the ones
based on whole group. All the analyses were conducted using
SAS, version 9.4.

Covariates
Demographic characteristics included age at the time of COVID19 diagnosis (18–49, ≥50), sex (female, male, and unknown), race
(White, Black or African American, Asian, and other/unknown),
and ethnicity (Hispanic or Latino, not Hispanic or Latino,
and unknown). We created a binary variable of rural/urban
residence according to the list of rural counties designated by the
Office of Rural Health Policy (27). We employed the Charlson
Comorbidity Index (CCI) to evaluate pre-existing comorbidity
conditions (28). The CCI scores (equal to 1, 2, 3, or 6) were
assigned based on the severity of each condition and derived by
adding the scores for all comorbidities in a particular patient.
Based on the distribution of CCI score in this cohort, we
classified the patients into 3 CCI categories (0, 1, ≥2).We
also included smoking status (never smoker, former smoker,
current smoker, other/unknown), an established lifestyle factor
associated with COVID-19 clinical outcomes as one of covariates
in statistical analysis (29).

Statistical Analysis
Descriptive statistics were computed for all study variables using
means and standard deviations (SD) for the continuous variables
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RESULTS

urban areas (87.0%). Over one half (54.0%) of the patients were
identified as asymptomatic cases, 33.3% as mild cases, and 12.7%
as moderate/severe cases. About 4.4% of all patients (n = 20,995)
were hospitalized and 1.9% (n = 8,924) died due to COVID-19.

Characteristics of Participants
Of the 476,775 adult COVID-19 patients included in the study,
421,475 patients had no recorded clinical diagnosis of a mental
disorder and 55,300 patients had at least one diagnosis of mental
disorders before the COVID-19 diagnosis (Table 2). Among the
overall sample, 58.3% were 18–49 years of age (mean = 45.7,
SD = 18.6), 52.9% were female, 47.6% were White, 20.4% were
Black, 5.1% were Hispanic/Latino, and the majority were living in

Pre-existing Mental Disorders
Of the 55,300 patients with pre-existing mental disorders,
23,410 (42.3%) had internalizing disorders only, 21,200 (38.3%)
had externalizing disorders only, and 618 (1.1%) had thought
disorders only. The number of individuals with a single cluster

TABLE 2 | Characteristics of the whole study population.
Characteristics

Overall

Any mental

Internalizing

Externalizing

Thought

population

disorder cluster

disorders

disorders

disorders

No

Yes

No

Yes

No

Yes

No

Yes

Age
18-49

277,988 (58.31) 249,969 (59.31) 28,019 (50.67) 263,832 (59.46) 14,156 (42.78) 259,275 (58.1) 18,713 (61.27) 276,914 (58.4) 1,074 (41.09)

50+

198,787 (41.69) 171,506 (40.69) 27,281 (49.33) 179,849 (40.54) 18,938 (57.22) 186,960 (41.9) 11,827 (38.73) 197,247 (41.6) 1,540 (58.91)

Gender
Female

252,292 (52.92) 219,867 (52.17) 32,425 (58.63) 229,550 (51.74) 22,742 (68.72) 237,537 (53.23) 14,755 (48.31) 251,014 (52.94) 1,278 (48.89)

Male

208,956 (43.83) 187,738 (44.54) 21,218 (38.37) 199,609 (44.99) 9,347 (28.24) 194,059 (43.49) 14,897 (48.78) 207,712 (43.81) 1,244 (47.59)

Unknown/missing

15,527 (3.26)

13,870 (3.29)

1,657 (3)

1,4522 (3.27)

1,005 (3.04)

14,639 (3.28)

888 (2.91)

15,435 (3.26)

92 (3.52)

Race
White

226,985 (47.61) 200,400 (47.55) 26,585 (48.07) 208,767 (47.05) 18,218 (55.05) 213,968 (47.95) 13,017 (42.62) 225,950 (47.65) 1,035 (39.59)

Black

97,066 (20.36) 82,522 (19.58) 14,544 (26.3) 90,289 (20.35) 6,777 (20.48) 87,672 (19.65) 9,394 (30.76) 96,192 (20.29)

Other/Unknown

149,240 (31.3) 135,179 (32.07) 14,061 (25.43) 141,213 (31.83) 8,027 (24.26) 141,162 (31.63) 8,078 (26.45) 148,541 (31.33) 699 (26.74)

874 (33.44)

Ethnicity
Not hispanic or latino
Hispanic or Latino
Unknown/missing

285,738 (59.93) 250,038 (59.32) 35,700 (64.56) 263,844 (59.47) 21,894 (66.16) 266,520 (59.73) 19,218 (62.93) 284,126 (59.92) 1,612 (61.67)
24,526 (5.14)

23,260 (5.52)

1,266 (2.29)

23,780 (5.36)

746 (2.25)

23,839 (5.34)

687 (2.25)

24,497 (5.17)

29 (1.11)

166,511 (34.92) 148,177 (35.16) 18334 (33.15) 156,057 (35.17) 10,454 (31.59) 155,876 (34.93) 10,635 (34.82) 165,538 (34.91) 973 (37.22)

Residence
Rural

61,816 (12.97) 53,448 (12.68) 8,368 (15.13) 57,133 (12.88) 4,683 (14.15) 56,944 (12.76) 4,872 (15.95) 61,432 (12.96)

Urban

414,959 (87.03) 368,027 (87.32) 46,932 (84.87) 386,548 (87.12) 28,411 (85.85) 389,291 (87.24) 25,668 (84.05) 412,729 (87.04) 2,230 (85.31)

384 (14.69)

Smoking
No

71,451 (14.99) 61,684 (14.64) 9,767 (17.66) 64,363 (14.51) 7,088 (21.42) 67,559 (15.14) 3,892 (12.74) 70,994 (14.97)

Former smoker

17,274 (3.62)

14,392 (3.41)

2,882 (5.21)

15,445 (3.48)

1,29 (5.53)

15,724 (3.52)

1,550 (5.08)

17,207 (3.63)

67 (2.56)

Current smoker

8,417 (1.77)

5,408 (1.28)

3,009 (5.44)

7,521 (1.7)

896 (2.71)

5,580 (1.25)

2,837 (9.29)

8,325 (1.76)

92 (3.52)

Other/Unknown

457 (17.48)

379,633 (79.63) 339,991 (80.67) 39,642 (71.69) 356,352 (80.32) 23,281 (70.35) 357,372 (80.09) 22,261 (72.89) 377,635 (79.64) 1,998 (76.43)

CCI score
0

375,705 (78.8) 356,688 (84.63) 19,017 (34.39) 367,602 (82.85) 8,103 (24.48) 362,533 (81.24) 13,172 (43.13) 375,110 (79.11) 595 (22.76)

1

28,531 (5.98)

≥2

72,539 (15.21) 45,066 (10.69) 27,473 (49.68) 52,844 (11.91) 19,695 (59.51) 60,143 (13.48) 12,396 (40.59) 70,62 (14.94) 1,677 (64.15)

19,721 (4.68)

8,810 (15.93)

23,235 (5.24)

5,296 (16.00)

23,559 (5.28)

4,972 (16.28)

28,189 (5.95)

342 (13.08)

COVID severity/syms
No/asymptomatic

257,254 (53.96) 226,574 (53.76) 30,680 (55.48) 239,324 (53.94) 17,930 (54.18) 239,666 (53.71) 17,588 (57.59) 255,553 (53.9) 1,701 (65.07)

Mild

158,960 (33.34) 143,639 (34.08) 15,321 (27.71) 150,046 (33.82) 8,914 (26.94) 150,623 (33.75) 8,337 (27.3) 158,395 (33.41) 565 (21.61)

Severe

60,561 (12.7)

51,262 (12.16) 9,299 (16.82) 54,311 (12.24) 6,250 (18.89) 55,946 (12.54) 4,615 (15.11)

60,213 (12.7)

348 (13.31)

COVID hospitalization
No
Yes

455,780 (95.6) 405,328 (96.17) 50,452 (91.23) 426,194 (96.06) 29,586 (89.4) 427,289 (95.75) 28,491 (93.29) 453,527 (95.65) 2,253 (86.19)
20,995 (4.4)

16147 (3.83)

4,848 (8.77)

17,487 (3.94)

3,508 (10.6)

18,946 (4.25)

2,049 (6.71)

20,634 (4.35)

361 (13.81)

Death
No
Yes

467,851 (98.13) 414,714 (98.4) 53,137 (96.09) 436,379 (98.35) 31,472 (95.1) 438,099 (98.18) 29,752 (97.42) 465,416 (98.16) 2,435 (93.15)
8,924 (1.87)

6,761 (1.6)

2,163 (3.91)

7,302 (1.65)

1,622 (4.9)

8,136 (1.82)

788 (2.58)

8,745 (1.84)

179 (6.85)

The results for Asian group were not reported due to policy. Chi-square tests for all the characteristics variables are all significant (i.e., P < 0.05).
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COVID-19 hospitalization (Internalizing disorders: 10.6 vs.
3.9%; Externalizing disorders: 6.7 vs. 4.3%; Thought disorders:
13.8 vs. 4.4%; Any mental disorder cluster: 8.8 vs. 3.8%) and
COVID-19-related deaths (Internalizing disorders: 4.9 vs. 1.7%;
Externalizing disorders: 2.6 vs. 1.8%; Thought disorders: 6.9 vs.
1.8%; Any mental disorder cluster: 3.9 vs. 1.6%). The association
between pre-existing mental disorders and COVID-19 severity
was more complicated. In general, participants with pre-existing
mental disorders had higher proportions of being asymptomatic
(Internalizing disorders: 54.2 vs. 53.9%; Externalizing disorders:
57.6 vs. 53.7%; Thought disorders: 65.1 vs. 53.9%; Any cluster of
mental disorders: 55.5 vs. 53.8%) and severe cases (Internalizing
disorders: 18.9 vs. 12.2%; Externalizing disorders: 15.1 vs. 12.5%;
Thought disorders: 13.3 vs. 12.7%; Any mental disorder cluster:
16.8 vs. 12.2%). However, they represented a lower proportion of
mild cases (Internalizing disorders: 26.9 vs. 33.8%; Externalizing
disorders: 27.3 vs. 33.8%; Thought disorders: 21.6 vs. 33.4%; Any
mental disorder cluster: 27.7 vs. 34.1%).

or multiple clusters of mental disorders is presented in Figure 1.
There were 8,076 (14.6%) patients who had both internalizing
and externalizing disorders, 732 (13.2%) had both internalizing
and thought disorders, and 388 (0.7%) had externalizing and
thought disorders. The number of patients having all three
clusters of internalizing, externalizing, and thought disorders
was 876 (1.6%).
Generally, we observed significant differences in age,
gender, race, ethnicity, residence, smoking status, and preexisting comorbidity conditions between participants with
and without pre-existing mental disorders (Table 2). For
example, there was a higher proportion of people who were
older, female, non-Hispanic/Latino, living in rural area and
with comorbidity conditions among participants with preexisting mental disorders, compared with those without these
disorders. However, the patterns of the socio-demographic
difference between participants with and without pre-existing
mental disorders varied by the mental disorder clusters. Higher
proportions of participants with internalizing disorders were
older (≥50 years), female, White, non-smokers, and lived in
rural areas. Higher proportions of participants with externalizing
disorders were males, Black/African American, former/ current
smokers, and lived in rural areas. We found that higher
proportions of participants with thought disorders were older
(≥50 years), Black/African American, non-smokers, and lived in
rural areas.

Multivariate Analysis
Adjusting for key socio-demographic and comorbidity
covariates (i.e., age, gender, race, ethnicity, residence, smoking,
comorbidity), the multivariate results suggest an elevated risk of
COVID-19-related hospitalization and death among participants
with pre-existing mental disorders except externalizing disorders
(Table 3). For COVID-19 hospitalization, the adjusted OR of
having internalizing disorders, externalizing disorders, and
thought disorders was 1.19 (95% CI: 1.130, 1.258), 0.931 (95%
CI: 0.867, 1.000), and 2.39 (95% CI: 1.899, 3.006), respectively.
Similarly, for COVID-19-related death, the aOR of having
internalizing disorders, externalizing disorders, and thought
disorders was 1.13 (95% CI: 1.056, 1.214), 0.775 (95% CI: 0.697,
0.860), and 2.34 (95% CI: 1.789, 3.052), respectively. However,

COVID-19 Clinical Outcomes
Among the 55,300 patients who had at least one pre-existing
mental disorder, 8.8% (n = 4,848) were hospitalized and
3.9% (n = 2,163) died due to COVID-19. Compared to
those without respective mental disorders, participants with
pre-existing mental disorders have a higher proportion of

FIGURE 1 | Venn diagram for comorbidity of mental disorders among the whole population: Sample in each mental disorder cluster. Not any mental disorders =
421,475; internalizing disorders only = 23,410; externalizing disorders only = 21,200; thought disorders only = 618; internalizing and externalizing disorders = 8,076;
internalizing and thought disorders = 732; externalizing and thought disorders = 388; internalizing, externalizing, and thought disorders = 876.
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TABLE 3 | Regression model results for COVID-19 outcomes adjusting for covariates in the whole study population.
Items

Severity (mild vs. no)

Severity (severe vs. no)

Hospitalization

Death

aOR (95%CI)

aOR (95%CI)

aOR (95%CI)

aOR (95%CI)

Age 50+ vs. 18–49

0, 711 (0.700, 0.723)

0.719 (0.703, 0.735)

6.171 (5.919, 6.435)

21.189 (19.015, 23.611)

Gender male vs. female

0.909 (0.895, 0.923)

0.828 (0.811, 0.845)

1.511 (1.464, 1.560)

1.567 (1.497, 1.639)

Gender unknown/missing vs. Female

0.916 (0.871, 0.963)

0.848 (0.789, 0.911)

0.762 (0.672, 0.865)

0.731 (0.610, 0.877)

Race black vs. white

0.820 (0.805, 0.836)

0.862 (0.841, 0.883)

1.839 (1.776, 1.906)

1.169 (1.109, 1.232)

Race Asian vs. white

1.041 (0.963, 1.124)

0.983 (0.881, 1.097)

1.528 (1.264, 1.848)

1.262 (0.931, 1.710)

Race other/unknown vs. white

0.253 (0.247, 0.259)

0.264 (0.254, 0.273)

0.868 (0.818, 0.921)

0.834 (0.770, 0.902)

Ethnicity hispanic or latino vs. not hispanic or latino

2.048 (1.979, 2.120)

2.449 (2.341, 2.563)

1.582 (1.462, 1.711)

0.961 (0.833, 1.108)

Ethnicity unknown/missing vs. not hispanic or latino

0.291 (0.285, 0.297)

0.277 (0.268, 0.285)

0.675 (0.642, 0.711)

0.877 (0.820, 0.939)

Urban vs. rural

1.050 (1.027, 1.074)

1.097 (1.065, 1.130)

0.905 (0.868, 0.944)

0.842 (0.794, 0.892)

Current smoker vs. No

0.899 (0.833, 0.971)

1.020 (0.940, 1.107)

0.594 (0.531, 0.666)

0.603 (0.500, 0.726)

Former smoker vs. No

1.478 (1.385, 1.578)

2.001 (1.870, 2.140)

0.892 (0.841, 0.947)

0.691 (0.632, 0.757)

Other/Unknown vs. No

0.096 (0.094, 0.099)

0.065 (0.063, 0.067)

0.931 (0.896, 0.967)

1.018 (0.963, 1.076)

CCI 1 vs. 0

0.808 (0.782, 0.835)

1.113 (1.068, 1.160)

1.559 (1.462, 1.663)

1.691 (1.532, 1.866)
3.969 (3.770, 4.179)

CCI ≥2 vs. 0

0.555 (0.541, 0.569)

0.940 (0.911, 0.969)

3.566 (3.437, 3.699)

Internalizing disorders Yes vs. No

0.850 (0.818, 0.884)

1.100 (1.051, 1.151)

1.192 (1.130, 1.258)

1.132 (1.056, 1.214)

Externalizing disorders Yes vs. No

0.736 (0.708, 0.765)

0.767 (0.730, 0.807)

0.931 (0.867, 1.000)

0.775 (0.697, 0.860)
2.336 (1.789, 3.052)

Thought disorders Yes vs. No

0.720 (0.575, 0.903)

0.768 (0.579, 1.017)

2.389 (1.899, 3.006)

Internal & external vs. No

0.577 (0.541, 0.615)

0.889 (0.826, 0.956)

1.262 (1.151, 1.383)

0.976 (0.858, 1.110)

Internal & thoughts vs. No

0.699 (0.568, 0.860)

0.981 (0.776, 1.241)

1.648 (1.298, 2.092)

1.509 (1.125, 2.023)

External & thoughts vs. No

0.562 (0.421, 0.749)

0.497 (0.335, 0.737)

1.759 (1.217, 2.542)

1.874 (1.222, 2.876)

Internal & external & thought vs. No

0.399 (0.326, 0.489)

0.496 (0.389, 0.631)

1.643 (1.274, 2.118)

0.779 (0.514, 1.181)

Symptom mild vs. asymptomatic

N/A

N/A

1.407 (1.343, 1.475)

0.859 (0.802, 0.920)

Symptom severe vs. asymptomatic

N/A

N/A

10.744 (10.285, 11.224)

4.887 (4.604, 5.187)

Bold OR indicate P < 0.05.

disorders (aOR = 1.51, 95% CI: 1.125, 2.023) and 87% greater
among patients with externalizing and thought disorders (aOR =
1.87, 95% CI: 1.222, 2.876) than the odds of having COVID-19related death among patients without pre-existing mental health.
Co-occurrence of any two clusters was negatively related with
mild cases. The odds of having mild symptoms decreased 42%
among patients with internalizing and externalizing disorders
(aOR = 0.58, 95% CI: 0.541, 0.615), 30% for patients with
internalizing and thoughts disorders (aOR = 0.70, 95% CI:
0.568, 0.860), 44% for patients with externalizing and thoughts
disorders (aOR = 0.56, 95% CI: 0.421, 0.749), and 60% for
patients with three clusters of mental orders (aOR = 0.40, 95%
CI: 0.326, 0.489) than the odds of having mild symptoms among
patients without pre-existing mental disorders. In addition, the
odds of having severe symptoms decreased by 11% for patients
with internalizing and externalizing disorders (aOR = 0.89, 95%
CI: 0.826, 0.956), by 50% among patients with externalizing and
thought disorders (aOR = 0.50, 95% CI: 0.335, 0.737), and by 50%
for patients with three clusters of mental disorders (aOR = 0.50,
95% CI: 0.389, 0.631) than the odds of having severe symptoms
among patients without pre-existing mental disorders.

pre-existing mental disorders were associated with decreased
risk of mild and severe cases. Specifically, having internalizing
disorders (aOR = 0.85, 95% CI: 0.818, 0.884), externalizing
disorders (aOR = 0.74, 95% CI: 0.708, 0.765), and thought
disorders (aOR = 0.72, 95% CI: 0.575, 0.903) were negatively
associated with mild cases. Having externalizing disorders (aOR
= 0.77; 95% CI: 0.730, 0.807) was negatively associated with
severe cases but having internalizing disorders (aOR = 1.10; 95%
CI: 1.051, 1.151) was positively associated with severe cases.
Co-occurrence of any two clusters was positively associated
with COVID-19 hospitalization and COVID-19-related death
(See the forest plot in Figure 2 and Table 3). Specifically, the odds
of being hospitalized was 26% greater among patients with the
presence of both internalizing and externalizing disorders (aOR
= 1.26; 95% CI: 1.151, 1.383) than the odds of being hospitalized
among those with no pre-existing mental disorders. We have 95%
confidence that the true parameter falls between 1.151 and 1.383.
The odds of being hospitalized was 65% greater among patients
with internalizing and thought disorders (aOR = 1.65; 95% CI:
1.298, 2.092), 76% greater among patients with externalizing
and thought disorders (aOR = 1.76; 95% CI: 1.217, 2.542),
and 64% greater among patients with three clusters of mental
disorders (aOR = 1.64; 95% CI: 1.274, 2.118) than the odds of
being hospitalized among patients without pre-existing mental
disorders. Similarly, the odds of having COVID-19-related death
were 51% greater among patients with internalizing and thought
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The results of subgroup analysis are presented in supplemental
tables (Appendix 1). In summary, the subgroup with health visits
(n = 221,288) was similar in terms of demographic characteristics
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FIGURE 2 | Forest plot of final regression models. Logarithm of odds ratio was used in developing the forest plots given large value of some odds ratios. We then use
zero instead of one as the criteria of significance. (A) Severity (mild vs. asymp); (B) severity (severe vs. asymp); (C) hospitalization (yes vs. no); (D) death (yes vs. no).

as the whole sample except older (50+ group: 51.6 vs. 41.7%)
with the uninsurance rate of 11.1%, which is close to the 12.7%
in general population in SC. Multivariate analysis among the
subgroup were comparable to the ones based on whole group.

lead to altered glucocorticoids and suppressed cell-mediated
and humoral immunity is widely reported among people
with mental disorders (30–33). The immune dysfunction,
subsequently, contributes to high risk of SARS-CoV-2 infection.
The inflammatory cytokine overproduction induced by
glucocorticoid receptor resistance may be responsible for the
damage of the lungs and correlates with disease deterioration and
fatal COVID-19 (34–36). Recent studies also indicate a genetic
association between psychiatric disorder and COVID-19 (37).
For example, one genome-wide association study suggests that
genetic liability to depression and substance misuse is associated
with severe COVID-19 outcomes (hospitalization or death) (38).
Internalizing disorders, like depression and anxiety disorders
have been found to be associated with immune-inflammatory
disturbances, which may contribute to severe COVID-19 clinical
outcomes (39, 40). The lifestyle changes following the occurrence
of internalizing disorders, such as smoking and alcohol abuse,
may also contribute to altered risk to COVID-19 infection and
worse outcomes. Externalizing disorders, especially long-term
use of tobacco, alcohol, and other drugs, are also closely related
to cardiovascular, pulmonary, and metabolic diseases, which
are high-risk preconditions for COVID-19 outcomes (41, 42).

DISCUSSION
Using a psychopathology structure model of mental disorders
(i.e., the three-factor model) and leveraging the EHR data from a
statewide cohort of COVID-19 patients in SC, United States, we
explored the association between pre-existing mental disorders
and COVID-19 clinic outcomes from a new perspective.
Our findings are aligned with existing evidence of a positive
association between pre-existing mental disorders and COVID19 related hospitalization and death. Several studies have
posited potential reasons and interpretations regarding the
underlying mechanism of pre-existing mental disorders
as a risk factor of COVID-19 clinical outcomes, including
immune dysregulation processes, genetic predisposition toward
psychiatric disorders, and health-compromising lifestyle (20).
The activation of the endocrine stress axis at different levels,
such as hypothalamic-pituitary-adrenal (HPA) axis which can
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Although our results suggest that pre-existing mental
disorders are risk factors of COVID-19-related hospitalization
and death, pre-existing mental disorders may be associated
with decreased risk of mild cases. Extant literature suggests
that pre-existing chronic illness and therapeutic options may
affect the prognosis of COVID-19 and have a possible protective
effect against COVID-19. For example, allergic sensitization in
asthma is related to lower expression of angiotensin-converting
enzyme 2 receptors showing a potential protective effect (53).
In addition, the use of inhaled corticosteroids is generally
safe and associated with decreased risk of hospitalization (54).
However, there is a dearth of evidence regarding whether
mental disorder treatments affect prognosis of COVID-19. Given
the high rate of comorbidity between mental disorders and
chronic somatic disease, the pre-existing chronic conditions
and the treatment among these patients could be complicated.
Further studies are needed to identify potential confounders
and explain the “protective effect” (54). In addition, the
high-risk drug-drug interactions that may occur in COVID19 treatment accompanied by psychotropic drug prescription
warrants multidisciplinary study engaging both psychiatrists and
infectious disease physicians (55).
Our findings need to be interpreted with caution due to
several limitations. First, our mental health data comes from
a health utilization dataset. Therefore, we were not able to
retrieve information of people who had mental disorders but
failed to access to healthcare system for any reasons. There is
also missing information in the COVID-19 data. The missing
data may impede the robustness of our findings. Second, the
study is subject to common limitations of using ICD10 codes
to define mental health disorders. As other EHR based studies
suggest, the quality of raw data may influence the validity of our
results. Fourth, we did not differentiate the severity category of
the mental disorders. For example, we did not explore if patients
with “acute” disorders have any different risk of worse COVID19 outcomes compared to those with “recurrent” (more severe
mental illness) disorders. Fifth, the EHR data is not able to cover
multiple socio-economic factor variables or socio-behavioral
variables, which could be critical risk factors of COVID-19
clinical outcomes. Finally, the theoretical frame of clustering
the mental disorders needs more empirical evidence for further
modification and refinement.
Despite these limitations, the current study sheds lights on
impacts of different mental disorder clusters and their cooccurrences on COVID-19 clinical outcomes using a large
statewide and real-world dataset. Our findings have significant
implications for improving surveillance and triage in COVID-19
treatment considering a high prevalence of psychiatric disorders
(20.6% as of 2019) in the general population (56). First, it is
critical to identify vulnerable subgroups in COVID-19 treatment.
Pre-existing thought disorders and co-occurrence of multiple
mental disorder clusters seem to be independent risk factors of
COVID-19-related hospitalization and death controlling other
background characteristics. Identifications of these risk factors
will assist triage and medical resource allocation so that the
healthcare providers can identify the most vulnerable subgroup
and prevent the disease deterioration among them.

In addition, we discovered that pre-existing thought disorders
(e.g., mania, schizophrenia, OCD) may be related to COVID-19
hospitalization and death in the greatest magnitude.
Thought disorders are usually considered as severe mental
disorders. A recent systematic review and meta-analysis on
the association between mental disorders and COVID-19 death
reports that people with severe mental disorders (defined as
schizophrenia and/or bipolar disorders) have the highest risk
of COVID-19 death (14). One national-level study conducted
in South Korea suggests that severe mental disorders (defined
as non-affective or affective disorders with psychotic features)
are more likely to be associated with severe clinical outcomes
(ICU admission, invasive ventilation, death) compared to other
mental disorders (10). People with thought disorders likely need
assistance and support from caregivers to follow healthcare
and COVID-19 mitigation measures such as mask wearing
and social distancing. Some prevention recommendations,
such as hand washing, can reinforce the irrational beliefs
of patients with OCD (43). The limited availability of
caregivers and tailored COVID-19 mitigation strategies during
the pandemic makes this group especially vulnerable to
COVID-19. In addition, the pre-existing disadvantages at
multiple socioecological levels among patients with severe
mental disorders have exacerbated the risks of COVIDrelated hospitalization and mortality. For example, people with
schizophrenia are often heavy smokers because nicotine may
temporarily lessen the symptoms of poor concentration, low
mood, and stress (44–46). They smoke at two to four times
the rate of the general population (47). Smokers with a mental
health disorder tend to smoke more cigarettes than those in
the general population (47). People with severe mental illness
also suffer from substantial weight-gain because of metabolic
syndrome and psychotropic agents, including antipsychotic
medications and antidepressants (48, 49). The higher prevalence
rates of cigarette smoking, chronic obstructive pulmonary
disease, overweight, hyper-glycaemia/diabetes, hypertension, and
cardiovascular disease among people with serious mental
illness compared to general population may directly increase
their risk of COVID-19 mortality (50). Beside the lifestyle
and physical problems, social/structural level factors such as
poverty, stigma and discrimination against mental health, social
isolation and loneliness also worsen their life circumstances
and impede them access to social support and timely/quality
healthcare services, resulting in severe COVID-19-related
clinical outcomes (51, 52).
We found that people with co-occurrence of any two clusters
of mental disorders have elevated risk of COVID-19-related
hospitalization and death compared to those with a single cluster
(e.g., either internalizing or externalizing disorder). Given that
having pre-existing thought disorders is a high-risk factor of
worse COVID-19 clinical outcomes, it is reasonable to expect that
co-occurrence of thought disorders and either internalizing or
externalizing disorders indicates more vulnerability compared to
the single cluster of pre-existing mental disorders. Notably, the
co-occurrence of internalizing and externalizing disorders has
increased risk of COVID-19-related hospitalization compared to
a single cluster.
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in data use agreements with our state agencies or other
data providers. Institutional policies stipulate that all external
requests for data access require collaboration with a (author’s
affiliation) researcher. For more information or to make
a request, please contact (BO): olatosi@mailbox.sc.edu. The
underlying analytical codes are available from the authors
on request.

Second, sociodemographic profiles of patients with
comorbidity of both COVID-19 and mental disorders
warrant further exploration. Our findings show that higher
proportions of patients with thought disorders were older
(≥50 years), Black/African American, and lived in rural areas.
Mounting evidence indicates mental health disparities in the
United States with racial/ethnic minorities and people living
in rural areas being disadvantaged in terms of medical and
mental health care resources. Furthermore, this group faces
higher risk of COVID-19 infection, endures more barriers to
access to health resources, and shows disproportionally high
morbidity and mortality of COVID-19. More empirical evidence
and policy studies are needed to illustrate and address the
intersection between mental health, COVID-19, and social
deprivation/vulnerability from the perspective of health equity
and structural racism.
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